The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
Background. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Gastroenterology Research and Practice |
| Online Access: | http://dx.doi.org/10.1155/2017/4585164 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832549904671571968 |
|---|---|
| author | Svein Oskar Frigstad Anne Haaber Antal Bajor Jan Fallingborg Per Hammarlund Ole K. Bonderup Håkan Blom Terje Rannem Per M. Hellström |
| author_facet | Svein Oskar Frigstad Anne Haaber Antal Bajor Jan Fallingborg Per Hammarlund Ole K. Bonderup Håkan Blom Terje Rannem Per M. Hellström |
| author_sort | Svein Oskar Frigstad |
| collection | DOAJ |
| description | Background. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside. Methods. A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year. Results. Out of 282 patients, 82 had Crohn’s disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients. Conclusion. Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction. This trial is registered with NCT01900197. |
| format | Article |
| id | doaj-art-00d16cf17d424726b1cd9019a6846e4d |
| institution | Kabale University |
| issn | 1687-6121 1687-630X |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Gastroenterology Research and Practice |
| spelling | doaj-art-00d16cf17d424726b1cd9019a6846e4d2025-02-03T06:08:10ZengWileyGastroenterology Research and Practice1687-61211687-630X2017-01-01201710.1155/2017/45851644585164The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron DeficiencySvein Oskar Frigstad0Anne Haaber1Antal Bajor2Jan Fallingborg3Per Hammarlund4Ole K. Bonderup5Håkan Blom6Terje Rannem7Per M. Hellström8Department of Medicine, Bærum Hospital, Vestre Viken Hospital Trust, Drammen, NorwayDepartment of Gastroenterology, Gentofte Hospital, Hellerup, DenmarkDepartment of Internal Medicine, Södra Älvsborg Hospital, Borås, SwedenDepartment of Gastroenterology and Hepatology, Aalborg University Hospital, Aalborg, DenmarkDepartment of Gastroenterology, Ängelholm Hospital, Ängelholm, SwedenDepartment of Gastroenterology, Silkeborg Regional Hospital, Silkeborg, DenmarkDepartment of Medicine, Sunderby Hospital, Luleå, SwedenDepartment of Gastroenterology, Nordsjælland Hospital, Frederikssund, DenmarkDepartment of Medical Sciences, Uppsala University, Uppsala, SwedenBackground. Intravenous iron allows for efficient and well-tolerated treatment in iron deficiency and is routinely used in diseases of the gastrointestinal tract. Objective. The aims of this study were to determine the probability of relapse of iron deficiency over time and to investigate treatment routine, effectiveness, and safety of iron isomaltoside. Methods. A total of 282 patients treated with iron isomaltoside were observed for two treatments or a minimum of one year. Results. Out of 282 patients, 82 had Crohn’s disease and 67 had ulcerative colitis. Another 133 patients had chronic blood loss, malabsorption, or malignancy. Patients who received an iron isomaltoside dose above 1000 mg had a 65% lower probability of needing retreatment compared with those given 1000 mg. A clinically significant treatment response was shown, but in 71/191 (37%) of patients, anaemia was not corrected. The mean dose given was 1100 mg, lower than the calculated total iron need of 1481 mg. Adverse drug reactions were reported in 4% of patients. Conclusion. Iron isomaltoside is effective with a good safety profile, and high doses reduce the need for retreatment over time. Several patients were anaemic after treatment, indicating that doses were inadequate for full iron correction. This trial is registered with NCT01900197.http://dx.doi.org/10.1155/2017/4585164 |
| spellingShingle | Svein Oskar Frigstad Anne Haaber Antal Bajor Jan Fallingborg Per Hammarlund Ole K. Bonderup Håkan Blom Terje Rannem Per M. Hellström The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency Gastroenterology Research and Practice |
| title | The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency |
| title_full | The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency |
| title_fullStr | The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency |
| title_full_unstemmed | The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency |
| title_short | The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency |
| title_sort | nimo scandinavian study a prospective observational study of iron isomaltoside treatment in patients with iron deficiency |
| url | http://dx.doi.org/10.1155/2017/4585164 |
| work_keys_str_mv | AT sveinoskarfrigstad thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT annehaaber thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT antalbajor thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT janfallingborg thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT perhammarlund thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT olekbonderup thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT hakanblom thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT terjerannem thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT permhellstrom thenimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT sveinoskarfrigstad nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT annehaaber nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT antalbajor nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT janfallingborg nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT perhammarlund nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT olekbonderup nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT hakanblom nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT terjerannem nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency AT permhellstrom nimoscandinavianstudyaprospectiveobservationalstudyofironisomaltosidetreatmentinpatientswithirondeficiency |